KRAS and neoplasm: As compared with reciprocal control KP or K mutant mice, KPY or KY mice showed a dramatic decrease in tumor burden as measured by tumor number and tumor size (large tumors, ≥ 1 mm2), respectively, indicating that YTHDF1 promotes the lung tumor progression driven by KRAS with or without Trp53 mutation (Fig. 3g, h, Supplementary Fig. 3e, f).